Infectious Microecology in Liver Disease

  • Lanjuan Li
Part of the Advanced Topics in Science and Technology in China book series (ATSTC)

Abstract

More than 100 years ago, Pavlov discovered that the liver can remove enteric toxins. Now we think that, under normal circumstances, the liver can also remove bacteria, fungi, and their metabolites such as toxins, endotoxin, ammonia, indoles, phenols, short-chain fatty acids (C4–C6), pseudo-nerve delivery mass precursors. Gnotobiote research reveals that intestinal flora and endotoxin in the liver increase the number of Kupffer cells and play an important role in the improvement. When the functioning of the liver suffers damage (including chronic hepatitis, alcoholic and non-alcoholic fatty liver disease, cirrhosis, severe hepatitis, liver transplantation, etc.), the system will incur a gut microflora imbalance in varying degrees, damage to the intestinal barrier and allowing intestinal bacteria and its metabolites to enter extra-intestinal organs (including blood) , resulting in abdominal infection, endotoxemia and so on. Meanwhile, the inflammatory stimuli activate the immune system excessively, which can cause an abnormal immune response, leading to systemic inflammatory response syndrome (SIRS) or multiple organ failure, such as gastrointestinal dysfunction or failure. Endotoxemia, and gastrointestinal dysfunction can also increase the imbalance in gut microflora, and further aggravate liver injury, a vicious cycle. Through a series of basic and clinical microbial research of liver diseases, we found that probiotics can adjust the gut microflora, repairing and improving the intestinal barrier function and reducing intestinal bacterial translocation, decreasing endotoxemia, reducing infection and improving the functioning of the liver.

Keywords

Placebo Hepatitis Carbon Monoxide Glutamine Prostaglandin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Cesaro C, Tiso A, Del Prete A, et al. Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis, 2011, 43:431–438.CrossRefPubMedGoogle Scholar
  2. [2]
    Kan Z, Madoff D C. Liver anatomy: Microcirculation of the liver. Semin Intervent Radiol, 2008, 25:77–85.PubMedCentralCrossRefPubMedGoogle Scholar
  3. [3]
    Roberts M S, Magnusson B M, Burczynski F J, et al. Enterohepatic circulation: Physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet, 2002, 41:751–790.CrossRefPubMedGoogle Scholar
  4. [4]
    Abt M C, Artis D. The intestinal microbiota in health and disease: The influence of microbial products on immune cell homeostasis. Curr Opin Gastroenterol, 2009, 25:496–502.CrossRefPubMedGoogle Scholar
  5. [5]
    Wheeler M D. Endotoxin and Kupffer cell activation in alcoholic liver disease. Alcohol Res Health, 2003, 27: 300–306.PubMedGoogle Scholar
  6. [6]
    Szabo G, Bala S. Alcoholic liver disease and the gut-liver axis. World J Gastroenterol, 2010, 16: 1321–1329.PubMedCentralCrossRefPubMedGoogle Scholar
  7. [7]
    Han DW. Intestinal endotoxemia as a pathogenetic mechanism in liver failure. World J Gastroenterol, 2002, 8: 961–965.CrossRefPubMedGoogle Scholar
  8. [8]
    Almeida J, Galhenage S, Yu J, et al. Gut flora and bacterial translocation in chronic liver disease. World J Gastroenterol, 2006, 12: 1493–1502.PubMedCentralPubMedGoogle Scholar
  9. [9]
    Bauer T M, Steinbruckner B, Brinkmann F E, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: Prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol, 2001, 96: 2962–2967.CrossRefPubMedGoogle Scholar
  10. [10]
    Madrid AM, Hurtado C, Venegas M, et al. Long-term treatment with cisapride and antibiotics in liver cirrhosis: Effect on small intestinal motility, bacterial overgrowth, and liver function. Am J Gastroenterol, 2001, 96: 1251–1255.CrossRefPubMedGoogle Scholar
  11. [11]
    Morencos F C, de las Heras Castano G, Martin Ramos L, et al. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci, 1995, 40: 1252–1256.CrossRefPubMedGoogle Scholar
  12. [12]
    Hashimoto N, Ohyanagi H. Effect of acute portal hypertension on gut mucosa. Hepatogastroenterology, 2002, 49: 1567–1570.PubMedGoogle Scholar
  13. [13]
    Wiest R, Rath H C. Gastrointestinal disorders of the critically ill. Bacterial translocation in the gut. Best Pract Res Clin Gastroenterol, 2003, 17: 397–425.CrossRefPubMedGoogle Scholar
  14. [14]
    Norman K, Pirlich M. Gastrointestinal tract in liver disease: Which organ is sick? Curr Opin Clin Nutr Metab Care, 2008, 11: 613–619.CrossRefPubMedGoogle Scholar
  15. [15]
    Garcia-Tsao G, Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004, 18: 353–372.CrossRefPubMedGoogle Scholar
  16. [16]
    Heidelbaugh J J, Sherbondy M. Cirrhosis and chronic liver failure: Part II. Complications and treatment. Am Fam Physician, 2006, 74: 767–776.PubMedGoogle Scholar
  17. [17]
    Yoshida H, Hamada T, Inuzuka S, et al. Bacterial infection in cirrhosis, with and without hepatocellular carcinoma. Am J Gastroenterol, 1993, 88: 2067–2071.PubMedGoogle Scholar
  18. [18]
    Deschenes M, Villeneuve J P. Risk factors for the development of bacterial infections in hospitalized patients with cirrhosis. Am J Gastroenterol, 1999, 94: 2193–2197.CrossRefPubMedGoogle Scholar
  19. [19]
    Caly W R, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol, 1993, 18: 353–358.CrossRefPubMedGoogle Scholar
  20. [20]
    Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: Variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology, 2001, 120: 726–748.CrossRefPubMedGoogle Scholar
  21. [21]
    Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis, 2008, 28: 26–42.CrossRefPubMedGoogle Scholar
  22. [22]
    Gines P, Angeli P, Lenz K, et al. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol, 2010, 53: 397–417.CrossRefGoogle Scholar
  23. [23]
    Nousbaum J B, Cadranel J F, Nahon P, et al. Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology, 2007, 45: 1275–1281.CrossRefPubMedGoogle Scholar
  24. [24]
    Evans L T, Kim W R, Poterucha J J, et al. Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology, 2003, 37: 897–901.CrossRefPubMedGoogle Scholar
  25. [25]
    Gonzalez A R, Gonzalez G M, Albillos M A. Physiopathology of bacterial translocation and spontaneous bacterial peritonitis in cirrhosis. Gastroenterol Hepatol, 2007, 30: 78–84.CrossRefGoogle Scholar
  26. [26]
    .Rasaratnam B, Connelly N, Chin-Dusting J. Nitric oxide and the hyperdynamic circulation in cirrhosis: Is there a role for selective intestinal decontamination? Clin Sci (Lond), 2004, 107: 425–434.CrossRefGoogle Scholar
  27. [27]
    Iwakiri Y, Groszmann R J. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology, 2006, 43(2 Suppl 1): 5121–5131.Google Scholar
  28. [28]
    Bass N M, Mullen K D, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med, 2010, 362: 1071–1081.CrossRefPubMedGoogle Scholar
  29. [29]
    Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double-blind, placebo-controlled trial. Hepatology, 1990, 12(4 Pt 1): 716–724.CrossRefPubMedGoogle Scholar
  30. [30]
    Rimola A, Bory F, Teres J, et al. Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage. Hepatology, 1985, 5: 463–467.CrossRefPubMedGoogle Scholar
  31. [31]
    Grange J D, Roulot D, Pelletier C, et al. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: A double-blind randomized trial. J Hepatol, 1998, 29: 430–436.CrossRefPubMedGoogle Scholar
  32. [32]
    Rasaratnam B, Kaye D, Jennings G, et al. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med, 2003, 139: 186–193.CrossRefPubMedGoogle Scholar
  33. [33]
    Novella M, Sola R, Soriano G, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology, 1997, 25: 532–536.CrossRefPubMedGoogle Scholar
  34. [34]
    Mattar A F, Drongowski R A, Coran A G, et al. Effect of probiotics on enterocyte bacterial translocation in vitro. Pediatr Surg Int, 2001, 17: 265–268.CrossRefPubMedGoogle Scholar
  35. [35]
    Adawi D, Ahrne S, Molin G. Effects of different probiotic strains of Lactobacillus and Bifidobacterium on bacterial translocation and liver injury in an acute liver injury model. Int J Food Microbiol, 2001, 70: 213–220.CrossRefPubMedGoogle Scholar
  36. [36]
    Rayes N, Seehofer D, Muller AR, et al. Influence of probiotics and fibre on the incidence of bacterial infections following major abdominal surgery — results of a prospective trial. Z Gastroenterol, 2002, 40: 869–876.CrossRefPubMedGoogle Scholar
  37. [37]
    Chiva M, Soriano G, Rochat I, et al. Effect of Lactobacillus johnsonii Lal and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis. J Hepatol, 2002, 37: 456–462.CrossRefPubMedGoogle Scholar
  38. [38]
    Riordan SM, Skinner N, Nagree A, et al. Peripheral blood mononuclear cell expression of toll-like receptors and relation to cytokine levels in cirrhosis. Hepatology, 2003, 37: 1154–1164.CrossRefPubMedGoogle Scholar
  39. [39]
    Liu Q, Duan Z P, Ha D K, et al. Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology, 2004, 39: 1441–1449.CrossRefPubMedGoogle Scholar
  40. [40]
    Asahara T, Takahashi M, Nomoto K, et al. Assessment of safety of lactobacillus strains based on resistance to host innate defense mechanisms. Clin Diagn Lab Immunol, 2003, 10: 169–173.PubMedCentralPubMedGoogle Scholar
  41. [41]
    Gurusamy K S, Kumar Y, Davidson B R. Methods of preventing bacterial sepsis and wound complications for liver transplantation. Cochrane Database Syst Rev, 2008: CD006660.Google Scholar

Copyright information

© Zhejiang University Press, Hangzhou and Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Lanjuan Li
    • 1
    • 2
  1. 1.The State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, School of MedicineZhejiang UniversityHangzhouChina
  2. 2.Collaborative Innovation Center for Diagnosis and Treatment of Infectious DiseasesHangzhouChina

Personalised recommendations